Prof. Daniel KAUFMANN

“I do not know what I may appear to the world, but to myself I seem to have been only like a boy playing on the sea-shore, and diverting myself in now and then finding a smoother pebble or a prettier shell than ordinary, whilst the great ocean of truth lay all undiscovered before me.” Isaac Newton

Daniel Kaufmann is a physician-scientist who currently holds the position of Chief of the Division of Infectious Diseases at the Lausanne University Hospital (CHUV) and is a Full Professor at the University of Lausanne. Before this, he trained and began his independent academic career in the USA, at Massachusetts General Hospital and Harvard University in Boston. He then moved to Canada and joined the University of Montreal and its affiliated hospital, where he conducted both bench and translational research. He also served as the director for the immunopathology research axis. In November 2022, after 21 years in North America, he returned to Europe to assume his current position.

Research topics

Dr Kaufmann’s laboratory delves into the immunovirology of HIV and SARS-CoV-2, aiming to pave the way for the development of vaccination and cure strategies. He is also more broadly interested on the impact of chronic inflammation on adaptive antiviral immunity. His research topics include:

  1. the understanding of effective CD4 help in antiviral immunity

  2. the molecular underpinnings of virus-specific T cell dysfunction

  3. single-cell studies of HIV reservoirs

  4. immunovirological factors that influence COVID-19 trajectories

  5. SARS-CoV-2 vaccine immunity in vulnerable populations.

 A recurring theme throughout his research is the continuous refinement of experimental techniques and the improvement of analytical methodologies. This overarching effort aims to effectively integrate clinical data with deep biomolecular profiling in the context of infectious diseases.


Open positions

  • PhD position available - Application link
  • Laboratory technician position available
 Last updated on 21/05/2024 at 08:05